Intermittent Fasting Benefits for Obesity & Type 2 Diabetes
Intermittent Energy Restriction Outperforms Time-Restricted Eating adn Continuous Energy Restriction for Type 2 Diabetes and Obesity
Table of Contents
A groundbreaking study presented at ENDO 2025, the Endocrine Society’s annual meeting, reveals that intermittent energy restriction (IER) may offer superior benefits for individuals managing type 2 diabetes and obesity compared to time-restricted eating (TRE) and continuous energy restriction (CER). The research,conducted by Haohao Zhang,Ph.D.,chief physician at The First Affiliated Hospital of zhengzhou University,provides crucial insights for clinicians seeking the most effective dietary strategies.
Key Findings: IER’s Distinct Advantages
The study, a single-center, randomized, parallel-controlled trial involving 90 patients, compared the effects of three distinct dietary interventions over a 16-week period. While all three approaches demonstrated improvements in blood sugar levels and body weight, IER emerged as the frontrunner in several key metabolic markers.
Superior Blood Glucose and Insulin Sensitivity Improvements
While HbA1c levels and overall weight loss showed no meaningful differences across the groups at the study’s conclusion, the IER group exhibited a greater absolute decrease in both HbA1c and body weight. More notably, IER considerably outperformed TRE and CER in:
Reducing fasting blood glucose: this indicates better immediate control over blood sugar spikes. Improving insulin sensitivity: Measured by the Matsuda index, this suggests the body’s cells became more responsive to insulin, a critical factor in managing type 2 diabetes.
* Lowering triglycerides: Elevated triglycerides are a common concern for individuals with diabetes and obesity, and IER showed a marked reduction.
Enhanced Adherence and Feasibility
Adherence to the dietary interventions was also a significant differentiator. The IER group reported the highest adherence rate at 85%, closely followed by the CER group at 84%. The TRE group showed a slightly lower adherence rate of 78%. This suggests that IER,despite its structured nature,is a feasible and enduring dietary approach for patients.
Study Design and Patient Profile
The randomized trial, which ran from November 19, 2021, to November 7, 2024, assigned 90 participants in a 1:1:1 ratio to the IER, TRE, or CER groups. All groups maintained consistent weekly caloric intake, with a team of nutritionists providing supervision throughout the 16-week intervention.
Of the 90 enrolled patients, 63 completed the study.The participant cohort comprised 18 females and 45 males, with an average age of 36.8 years. On average, participants had a diabetes duration of 1.5 years, a baseline BMI of 31.7 kg/m²,and a baseline HbA1c of 7.42%.
Adverse Events and Safety
Adverse events were reported as similar across all three groups,with mild hypoglycemia occurring in two patients in the IER group,two in the TRE group,and three in the CER group. Uric acid and liver enzyme levels remained statistically unchanged from baseline in all study groups, indicating a favorable safety profile for all interventions.
Implications for Clinical Practice
“The research fills a gap in directly comparing 5:2 intermittent energy restriction with a 10-hour time-restricted eating in patients with obesity and type 2 diabetes,” stated Zhang. “The findings provide scientific evidence for clinicians to choose appropriate dietary strategies when treating such patients.”
The study underscores the potential of dietary interventions as a cornerstone in the management of obesity and type 2 diabetes, with IER demonstrating a promising edge in metabolic control and patient adherence.